Five things for pharma marketers to know: Friday, May 18, 2018
The FDA has approved the first preventative migraine treatment from Amgen. Aimovig is the first drug specifically approved to prevent migraines, while other treatments used to prevent the ailment were designed to treat other diseases, like high blood pressure. (New York Times) Amgen has been running an unbranded migraine awareness campaign, called Speak Your Migraine, since last summer. (MM&M)
The first non-opioid drug to treat opioid withdrawal was also approved. The drug was developed by US WorldMeds. Previous methods for treating opioid withdrawal included giving people a safer opioid medicine like methadone to combat symptoms. (CNBC)
The NIH halted enrollment for a study on the benefits of moderate drinking. Agency officials are investigating whether employees solicited money from alcohol companies to fund the trial. Five liquor and beer companies are providing about $67 million of the $100 million cost of the 10-year study. (New York Times)
The Trump administration plans to block federal funds to abortion clinics. The administration is set to announce a change to Title X funding that would require the physical and financial separation between Title X services and organizations that perform, support, or refer to abortion as a method of family planning. The move would strip Title X funding from Planned Parenthood and other clinics that provide abortions alongside other health services. (Wall Street Journal)
If you missed the MM&M Transforming Healthcare conference, fear not. We have recaps of the day's sessions on who is leading disruption in healthcare, how Amazon's culture fuels its innovation, and soundbites on tech driving collaboration in healthcare and boosting patient-level outcomes.